AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03428412 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TCM placebo and conventional drug
Description: All patients were treated with medicine based on 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Chinese Treatment Guidelines for AECOPD.~The control group will receive TCM placebo according to the TCM syndrome. Placebo Sanhanhuayin granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of external cold and internal fluid in 14 treatment days.~Placebo Qingrehuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-heat congesting lung in 14 treatment days.~Placebo Zaoshihuatan granule (Jiangyin Tian Jiang Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for syndrome of phlegm-damp amassing in lung in 14 treatment days.
Study NCT04169594 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 3D Gait Analysis with Statistical Parametric Mapping
Description: A 3D motion capture system will be used for gait analysis. Vector field statistics will be used to simplify the clinical interpretation of time varying movement patterns.
Study NCT03197337 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pressure-test
Description: Pressure will be applied to the posterior fornix using a speculum.
Study NCT04076397 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: autologous transplant reinjection
Description: The patient is placed under loco-regional anesthesia. After sterilization of the upper limb and abdomen, the fat is removed at a fold by micro-incision by the Coleman method. The fat is decanted and micro-reinjected into the pulp of the patient's finger with 2 or 3 punctiform incisions. The quantity of fat injected is 2 to 3 mL. Incision of the abdomen and fingers is closed by points at monocryl 4/0. Finally, a fatty dressing is performed on the finger. Patients will benefit from nursing care every 2 days
Study NCT04076397 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: desensitization
Description: Patients will have to stimulate the pulp of your finger on a daily basis
Study NCT04314726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amelogenin
Description: amelogenins applied on the distal surface of the lower second molar after adjacent third molar extraction
Study NCT04314726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo applied on the distal surface of the lower second molar after adjacent third molar extraction
Study NCT01845402 — intervention group
Intervention type: BIOLOGICAL
Intervention: blood and urine samples
Description: A blood sample and urine sample will be collected for purpose of the study. CKD (Chronic kidney injury) will be diagnosed according to the KDIGO criteria in children.
Study NCT03347357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus was administered orally at a dose of 0.05 mg/kg/dose twice daily (bid) for children with nephrotic syndrome.
Study NCT00101413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: BAY43-9006 400 mg bid X 28 day cycles \[Continuous treatment for a maximum of 2 years; potential for compassionate use and long term survival follow-up post drug discontinuation.
Study NCT01140113 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Ultrafiltration
Description: After weaning from bypass patients had undergone to modified ultrafiltration for 15 minutes with a filtration flow at 300 ml/min
Study NCT00858013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nateglinide
Description: Nateglinide 90\~120mg three times a day
Study NCT00858013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Glimepiride 1\~2mg once a day
Study NCT02399696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Care-Brief Mindfulness Program
Description: A 4-week group program adapted from the 8-week Mindfulness Based Stress Reduction (MBSR) curriculum
Study NCT02399696 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Primary Care-Treatment as Usual
Description: Typical VA primary care treatment, including mental health services delivered by primary care staff.
Study NCT03808883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TGNC Directed Advocacy Meetings
Description: Series of 18 meetings with TGNC cohort, including 3 facilitated dialogues with the healthcare participants, to articulate barriers to access and to enter into dialogue with medical providers and staff.
Study NCT03808883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitated Dialogues between TGNC Cohort and Healthcare Participants
Description: Healthcare Participants attend a facilitated dialogue with the TGNC cohort. 3 total facilitated dialogues were held, but each healthcare participant attends only 1 session.
Study NCT00158054 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced depression care
Description: Initial patient preference for problem-solving therapy and/or pharmacotherapy, then a stepped-care approach.
Study NCT00158054 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Referred depression care
Description: Physician notified of depression symptoms, usual care followed.
Study NCT04676568 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extravesical VVF repair
Description: Both standard transvesical and extravesical approach for VVF repair will be utilised
Study NCT02947217 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine
Description: Inactivated influenza vaccine indicated for immunization against disease caused by influenza virus subtype A and type B present in the vaccine. Approved for use in persons 5 years of age and older. Single Dose prefilled 0.5 ml syringe.
Study NCT02947217 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Saline
Description: 0.5 mL of sterile Saline administered im
Study NCT02032719 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smartphone-assisted health coaching
Description: smartphone with software provides self monitoring of exercise, diet and stress reduction; provision of timely reminders; photo-journaling of meals; secure text messaging
Study NCT02032719 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counseling
Description: Lifestyle counseling
Study NCT01305434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Mulberry leaf extract effect on post prandial blood glucose
Description: Mulberry leaf extract (400 mg, Mulberry Zuccarin, New Nordic) or placebo will be administered with meals to type 2 diabetics. Half the patients will receive mulberry leaf extract for the first two weeks and half will receive placebo. Following a one week wash out period, the interventions will be reversed for another 2 weeks, followed by a final wash out period. Subjects will keep diaries of food, exercise, daily fasting glucose, and at least one 2 hour pc glucose per day for the 6 weeks of the trial.~Baseline renal function blood work and urine, liver function blood work, hemoglobin A1C, weight, and blood pressure will be done. These will be repeated at the end of each subject's 6 weeks in the trial. In addition, blood pressure will be checked with the distribution of the each 2 week batch of medications.
Study NCT01586299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 10 mg/kg every 8 hours until 24 hours after resolution of fever
Study NCT01586299 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 15 mg/kg every 6 hours until 24 hours after resolution of fever
Study NCT01434134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Tablet, target dose 100 mg once daily
Study NCT01434134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, target dose 100 mg once daily
Study NCT01434134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: Tablet, target dose 32 mg once daily
Study NCT01434134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, 32 mg once daily
Study NCT01505946 — intervention group
Intervention type: OTHER
Intervention: TGA (Thrombin generation Assay)
Description: TGA will be performed on plasma in order to evaluate differences in the ability to stimulate the thrombin generation among the different class of FVIII concentrates and possibly identify the most effective. The TGA will be quarterly repeated in order to verify if it is also adequate to check the therapy effectiveness during the study period
Study NCT01641172 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Dexa scan
Description: the DEXA scan to measure bone and fat will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have a DEXA scan at baseline, 1 month after the end of chemotherapy and after 1 year.
Study NCT01641172 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dexa scan
Description: the DEXA scan to measure bone and fat will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have a DEXA scan at baseline, 1 month after the end of chemotherapy and after 1 year.
Study NCT01641172 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: audiogram
Description: the audiogram will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have an audiogram at baseline, 1 month after the end of chemotherapy and after 1 year.
Study NCT04251208 — intervention group
Intervention type: OTHER
Intervention: Observational Study
Description: No intervention will be administered.
Study NCT02712372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4831
Description: AZD4831 1-50 mg/g oral suspension
Study NCT01641172 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: audiogram
Description: the audiogram will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have an audiogram at baseline, 1 month after the end of chemotherapy and after 1 year.
Study NCT01641172 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: measurement of heart rate variability and baroreflex sensitivity
Description: the measurements (continuous assessment of heart rate and blood pressure using an non-invasive Finapress device) during 30 minutes will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have those measurements taken at baseline, 1 month after the end of chemotherapy and after 1 year.
Study NCT02712372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD4831 placebo
Description: AZD4831 placebo oral suspension
Study NCT01980342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Healthy women who are using Nexplanon will be asked to take a 2-week course of reduced-dose efavirenz (400 mg daily).
Study NCT00609284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: D-7, D1, D8, D15, D22, D29, D43, D50
Study NCT00609284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: D-7, D1, D8, D15, D22, D29, D43, D50
Study NCT00609284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin, 5FU concomitant
Description: Carboplatin 70mg/m²/D ; 5FU 600 mg/m²/D, D1-4, D22-25, D43-46
Study NCT00609284 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 70 Gy in 7 weeks
Study NCT00609284 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 70 Gy in 7 weeks
Study NCT00635518 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Ten Steps for Healthy Feeding children programme
Description: Ten Steps for Healthy Feeding children
Study NCT03964636 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: OCT-A (optical coherence tomography)
Description: Included patients will have an OCT-A and will be questioned about their medical and ophthalmologic history, and their oestro-progestative contraceptive intake.
Study NCT02166320 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Partially covered SEMS
Study NCT02166320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fully covered SEMS
Study NCT03103074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum B Toxin
Description: Intradermal injections
Study NCT04646980 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Biobran/MGN-3
Description: Biobran/MGN3 is defined by the Medicines and Healthcare products Regulatory Agency (MHRA) as a food supplement. Biobran/MGN3 is manufactured by hydrolyzing rice bran with the enzymatic extract of medicinal Shiitake mushrooms. Enzyme hydrolysis of rice bran produces arabinoxylane, a hemi-cellulose compound, which constitutes the active ingredient of biobran/MGN3.
Study NCT04646980 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, with same appearance and taste as Biobran/MGN-3, was given to control subjects at a dose of 500 mg everyday for 3 months
Study NCT00665496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: Vardenafil 10 mg and 20 mg orally once a day as needed
Study NCT00665496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT03747458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPN-375
Description: OPN-375, BID
Study NCT03103074 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Saline
Description: Intradermal injections
Study NCT00523328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG9924
Description: dosage administered as per Biogen-idec protocol
Study NCT01641172 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: measurement of heart rate variability and baroreflex sensitivity
Description: the measurements (continuous assessment of heart rate and blood pressure using an non-invasive Finapress device) during 30 minutes will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have those measurements taken at baseline, 1 month after the end of chemotherapy and after 1 year.
Study NCT01641172 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Glucose tolerance assessment
Description: Glucose tolerance will be assessed by drinking glucose water and measuring glucose at baseline and 2 hours later. It will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have an assessment at baseline, 1 month after the end of chemotherapy and after 1 year.
Study NCT01641172 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Glucose tolerance assessment
Description: Glucose tolerance will be assessed by drinking glucose water and measuring glucose at baseline and 2 hours later. It will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.~The patients in the longitudinal part of the study will have an assessment at baseline, 1 month after the end of chemotherapy and after 1 year.
Study NCT01641172 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: oral nutrition supplements
Description: a set of 10 Oral Nutrition Supplements (ONS) will be offered combined with a questionnaire to measure appreciation and preference for these food products. All these tests and questionnaires will be performed longitudinally (before the first chemotherapy, on day 7 of the first course, before the second course, on day 7 of the second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy) and cross-sectional (1, 3, 5 and 7 years after chemotherapy).
Study NCT01641172 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: oral nutrition supplements
Description: a set of 10 Oral Nutrition Supplements (ONS) will be offered combined with a questionnaire to measure appreciation and preference for these food products. All these tests and questionnaires will be performed longitudinally (before the first chemotherapy, on day 7 of the first course, before the second course, on day 7 of the second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy) and cross-sectional (1, 3, 5 and 7 years after chemotherapy).
Study NCT01641172 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Two day food records
Description: Two day food records will be used to investigate the actual dietary intake before the first and second course, during (on day 5 and 6) first and second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy.
Study NCT01641172 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Two day food records
Description: Two day food records will be used to investigate the actual dietary intake before the first and second course, during (on day 5 and 6) first and second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy.
Study NCT01641172 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Food Frequency Questionnaire
Description: A Food Frequency Questionnaire (FFQ) will be used to investigate the usual dietary intake before the start of the first course, before and after the second course, 1 month after start of the last course, seven months after the start of chemotherapy, and 1 year after the start of chemotherapy (longitudinal), and 1, 3, 5 and 7 years after chemotherapy (cross-sectional).
Study NCT01641172 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food Frequency Questionnaire
Description: A Food Frequency Questionnaire (FFQ) will be used to investigate the usual dietary intake before the start of the first course, before and after the second course, 1 month after start of the last course, seven months after the start of chemotherapy, and 1 year after the start of chemotherapy (longitudinal), and 1, 3, 5 and 7 years after chemotherapy (cross-sectional).
Study NCT01564199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salmeterol / fluticasone propionate
Description: 100/1000 μg oral capsule
Study NCT04208802 — intervention group
Intervention type: OTHER
Intervention: Use of fluoridated toothpaste
Description: Use of fluoridated toothpaste
Study NCT04208802 — intervention group
Intervention type: OTHER
Intervention: Wearing of an intraoral device with bovine tooth samples
Description: Wearing of an intraoral device with bovine tooth samples
Study NCT04208802 — intervention group
Intervention type: OTHER
Intervention: Wearing of an intraoral device with resin samples
Description: Wearing of an intraoral device with resin samples
Study NCT02066441 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bio-D-Mulsion Forte®
Description: According to the company's literature, Bio-D-Mulsion Forte® contains: vitamin D (as cholecalciferol), a water and gum Arabic emulsifier base, and sesame oil. This product is documented online at the following web address: http://www.bioticsresearch.com/node/1570
Study NCT02066441 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03874650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity Planning Group
Description: Participants in this group will receive 8 1-hour sessions of Behavioural Activation combined with select Goal Management Training strategies over the course of 8 weeks.
Study NCT03874650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity Engagement Group
Description: Participants in this group will attend 8 1-hour sessions of various social activities such as board games and puzzles.
Study NCT03874650 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Waitlist Group
Description: Participants in this group will continue on their care as usual before being re-randomised into either the Activity Planning Group or Activity Engagement Group after 8 weeks.
Study NCT00414648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: A sirolimus dose of 2 tablets (1 mg/tablet) per day for 1 year.
Study NCT00414648 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo dose of 2 tablets per day for 1 year.
Study NCT02045719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: uncaria tomentosa (cat´s claw)
Study NCT01569919 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TroVax®
Description: Dose of 1 x 10\^9 TCID 50/ml, in 1ml, given on day 1 of weeks 1, 3, 6, 9, 12, 15, 18, 21, 24.
Study NCT01569919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m\^2 over 10 mins, given on day 3 of weeks 4, 7, 10, 13.
Study NCT01569919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m\^2 over 1 hour, given on day 3 of weeks 4, 7, 10, 13